Market Access GSK’s Nucala secures NICE COPD endorsement Pharmaceutical TechnologyNICE now recommends Nucala for both severe asthma and COPD, expanding the drug's clinical uptake across the UK's public health service.RespiratoryRead full story pharminent May 29, 2026 (Last updated: May 29, 2026) Pharmaceutical Technology NICE now recommends Nucala for both severe asthma and COPD, expanding the drug’s clinical uptake across the UK’s public health service. Respiratory Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Ahead of ASCO data drop, AZ gets key Imfinzi approvalNext: Pfizer bets up to $10.5B in 12-candidate cancer collab with China’s Innovent Related Stories Market Access pharminent June 12, 2026 Market Access Aquipta recommended by NICE for acute migraine treatment pharminent June 10, 2026 Market Access AbbVie’s migraine drug cleared for migraine attacks on NHS pharminent June 10, 2026
